Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417675 | 1.00 | PTGS1 (0.48) | PTGS1CES2ALDH5A1ABATRPS6KA3 | |
| SCHEMBL6856533 | 0.84 | CES2 (0.41) | CES2RPS6KA3JAK3POLBALDH1A1 | |
| SCHEMBL66819 | 0.84 | CES2 (0.46) | CES2RPS6KA3JAK3POLBMAPT | |
| SCHEMBL26070078 | 0.81 | PTGS1 (0.66) | PTGS1POLBMAPTLCKALDH1A1 | |
| SCHEMBL848186 | 0.79 | GABRA1 (0.60) | ALDH5A1ABATLCKALDH1A1 | |
| SCHEMBL18002465 | 0.77 | MAPT (0.49) | POLBMAPTL3MBTL1IDO1 | |
| SCHEMBL18002229 | 0.77 | AHR (0.41) | PTGS1CES2RPS6KA3JAK3NQO2 | |
| SCHEMBL478113 | 0.77 | KIF11 (0.38) | CES2RPS6KA3JAK3POLBALDH1A1 | |
| SCHEMBL30070463 | 0.77 | KIF11 (0.38) | CES2RPS6KA3JAK3POLBALDH1A1 | |
| SCHEMBL69029 | 0.77 | PTGS1 (0.52) | PTGS1CES2LCKALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE CORP (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4431098-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE Corporation (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-20240150342-A1 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2024-05-09 | — | — | US | disclosed |
| CN-115551846-B | 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-4045503-B1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERR-ALPHA) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2023-12-06 | — | — | EP | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2017197192-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| CN-105408325-A | Cyanotriazole compounds | OTSUKA PHARMA CO LTD | 2016-03-16 | — | — | CN | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| WO-2009143018-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691975-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | PTGS1 1069/4885CES2 336/4885ALDH5A1 3220/4885 |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, ACSL6 | PTGS1 657/4885CES2 596/4885ALDH5A1 744/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | PTGS1 657/4885CES2 596/4885ALDH5A1 744/4885 |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | CYP21A2, HSD11B2, MC2R | PTGS1 3328/4885CES2 2697/4885ALDH5A1 1483/4885 |
| US-20240150342-A1 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | ESRRA, ESR2, ESRRB | PTGS1 755/4885CES2 2969/4885ALDH5A1 1015/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | PTGS1 2094/4885CES2 314/4885ALDH5A1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.